Sentences with phrase «cell lung»

Further analysis showed some of the activated genes were enriched in small cell lung cancer and other cancer - promoting pathways.

Some types of lung cancer — for example, small cell lung cancer — are often diagnosed after the cancer has already spread.

For patients with non-small cell lung cancer with brain metastases, treatment with whole brain radiotherapy may not offer much benefit.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

In September oncologists reported they sequenced deadly squamous cell lung cancer in 178 patients.

LKB1 Inactivation Dictates Therapeutic Response of Nonsmall Cell Lung Cancer to the Metabolism Drug Phenformin

These genes, dormant in adults, often become reactivated in a type of cancer known as non-small cell lung tumors.

Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c - Kit in small cell lung cancer cells.

The late Paul Kalanithi, a non-smoking neurosurgeon, was diagnosed with squamous cell lung cancer.

The international early Phase II trial led by a team based at the Oxford Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this group.

Assessment of predictive markers and patient stratification for treatment regimens for lung cancer: FGFR1 amplification is a potential driving oncogene in lung squamous cell cancer (SCC), a subtype of non-small cell lung carcinoma (NSCLC).

More information: Maryna Perepelyuk et al, Evaluation of MUC1 - Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA - 29b to Nonsmall Cell Lung Cancer, Molecular Pharmaceutics (2018).

This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).

The company has been trying to win FDA approval for Opdivo to be used as a first option treatment for non-small cell lung cancer (NSCLC).

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

NEW YORK / CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly - diagnosed patients with advanced non-small cell lung cancer in a closely - watched study, cementing its lead position over Bristol - Myers Squibb Co and others in the most lucrative oncology market.

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

With lung cancer, for example, it wants to be able to resolve whether a test shows non-small-cell lung carcinoma or small cell lung carcinoma.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

Merck KGaA has released data showing some effectiveness in patients with ovarian cancer and non-small cell lung cancer, and plans more disclosures at medical conferences next year.

Merck already has an FDA approved immunotherapy drug with KEYTRUDA, a treatment for non-small cell lung cancer.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

Non — small cell lung cancer may involve genetic aberrations that can be used to direct therapy.

A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SCLC).

15 % of people with lung cancer have Small Cell Lung Cancer.

«Cause of chemoresistance in small cell lung cancer discovered.»

The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought.

Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first - line treatment for non-small cell lung cancer (NSCLC).

The company has four products in clinical development to treat small - cell lung cancer, cervical intraneoplasia, B - cell lymphoma, and hepatitis C.

Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.

The study, published April 4 in the journal The Lancet Oncology, focused on non-small cell lung cancer, which is the most common form of lung cancer.

«We found that the combination of pembrolizumab and chemotherapies evaluated thus far — in patients with advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)-- appears to be safe,» said Dr. Glen Weiss, Director of Clinical Research and Medical Oncologist at CTCA ® at Western, where he currently supervises more than 30 clinical trials involving hundreds of patients.

The abstract title was: Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit.?

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

«If 10 years ago you were talking about defining a five - year survival rate for metastatic non-small cell lung cancer patients, someone would laugh in your face.

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression - free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.

Dr. Weiss» study of pembrolizumab was presented during a session on small cell lung cancer when the theme of the conference was Science Drives Lung Cancer Advances.

The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.

One, in which Dr. Weiss was the senior author, highlighted the extended survival of metastatic small cell lung cancer (SCLC) patients who received statins.

«Link between inherited genetic variations, outcomes of non-small cell lung cancer patients discovered.»

«We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer.»